A phase IIa multicenter, randomized, double-blind, double-dummy, and placebo- and active controlled study to investigate the safety and efficacy of JNJ-18038683 administered to subjects with major depressive disorder
Latest Information Update: 10 Nov 2021
At a glance
- Drugs JNJ 18038683 (Primary) ; Escitalopram
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Janssen Research & Development
- 14 Dec 2010 Actual initiation date changed from 1 Nov 2007 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 14 Dec 2010 Actual initiation date changed from 1 Nov 2007 to 1 Dec 2007 as reported by ClinicalTrials.gov.
- 05 Feb 2009 Actual end date (Dec 2008) added as reported by ClinicalTrials.gov.